Moderna announced a strategic partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to use its mRNA platform to accelerate vaccine development.

“New partnership will harness Moderna’s mRNA rapid-response platform, clinically validated during the COVID-19 pandemic, to accelerate epidemic and pandemic vaccine development. First project will enable rapid pre-clinical testing of antigen designs for high-risk viral families, to advance global outbreak readiness,” Moderna wrote.

Moderna’s mRNA COVID-19 shots have horrific side effects, and the pharmaceutical company wants to develop them even faster.

They want to expand the usage of the dangerous platform to other ‘viral diseases.’

“We are pleased to announce our strategic partnership with CEPI, harnessing the power of Moderna’s mRNA platform to accelerate the development of mRNA vaccines against viral disease outbreaks that pose global public health threats. Our mRNA Access program reinforces our dedication to public health by offering researchers the opportunity to utilize our mRNA technology in the development of vaccines for emerging and neglected infectious diseases. We believe this program can play a key role in helping the next generation of researchers and engineers to advance mRNA science,” Moderna CEO Stéphane Bancel said.

“Future outbreaks are inevitable, but another pandemic is not. Thanks to the scientific and technological innovations advanced during COVID-19, the world now has the tools and capabilities to prevent the next outbreak from spiraling into a global catastrophe. Chief among them is the now proven mRNA vaccine technology, which can be used to develop safe and effective vaccines with remarkable speed that can be rapidly manufactured at scale. Our partnership with Moderna will harness the company’s clinically validated mRNA platform and its world-leading team of scientists to help prepare to respond to future epidemic and pandemic threats in as little as 100 days,” CEPI CEO Dr. Richard Hatchett said.

“Safe and effective!”

There are those two words again.

Those are two things Moderna’s mRNA COVID-19 shots definitely are NOT!

More like dangerous and useless!

Cont. from Moderna:

The partnership will kick off with an initial project to evaluate the performance of novel AI-generated antigen designs and mRNA technology against a range of viral families that carry the greatest risk of causing the next pandemic. Building upon Moderna’s existing mRNA Access program, CEPI-funded vaccine researchers will send their cutting-edge computational antigen designs to Moderna, who will rapidly manufacture the related vaccine candidates using Moderna’s mRNA platform technology to provide material for preclinical testing funded by CEPI.

The project will enable CEPI-funded researchers to swiftly test multiple antigen designs targeting a specific viral family and quickly identify which, if any, are most promising. It will also generate data on the performance of mRNA vaccine technology against selected viral families and assess the suitability and effectiveness of mRNA for different disease targets. This would contribute vital scientific knowledge to inform further vaccine development targets and could give the world a headstart in response to future emerging outbreaks to advance the 100 Days Mission.

CEPI and Moderna will discuss additional vaccine development projects which fall under the remit of this strategic partnership, with further announcements to follow in due course.

Enabling Equitable Access

CEPI and Moderna are committed to enabling equitable access to the outputs of this strategic partnership. CEPI will retain rights to antigen designs which have been generated using CEPI funding, with CEPI-funded partners committed to submitting their data generated by this project for publication in open-access journals for the benefit of the global scientific community.

Any licensed vaccines developed as a result of this strategic partnership are expected to be made available at affordable prices in low- and middle-income countries.


CEPI and Moderna

CEPI and Moderna first worked together in early 2020, when CEPI provided early catalytic investment of $0.9 million to support the production of Moderna’s COVID-19 vaccine (mRNA-1273).

“CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need,” the press release added.

“CEPI has supported the development of over 30 vaccine candidates against its priority pathogens-Chikungunya virus, Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and SARS-CoV-2-and is a leading funder of research into broadly protective coronavirus vaccines, which could protect against future variants of COVID-19 as well as other coronaviruses with epidemic and pandemic potential. The organization has also invested in the development of rapid response platforms to develop vaccines against Disease X (the threat of an unknown virus),” the release continued.

“CEPI’s five-year plan for 2022-2026 aims to dramatically reduce or even eliminate the future risk of pandemics and epidemics. Central to the plan is CEPI’s goal to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days. Achieving this ‘100 Days Mission’, which has been embraced by the G7 and G20, would give the world a fighting chance of containing a future outbreak before it can spread to become a global pandemic,” the release added.

Read more about CEPI’s “Delivering Pandemic Vaccines in 100 Days” report HERE.

Join The Conversation. Leave a Comment.

We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spam, instead of replying to it please click the ∨ icon below and to the right of that comment. Thank you for partnering with us to maintain fruitful conversation.